Financial Data and Key Metrics Changes - Net revenue for Q2 2026 was $15.2 million, down from $16.2 million in the prior year, with ADHD portfolio revenue at $13.2 million compared to $13.8 million last year [19][20] - Gross margin decreased to 63.5% from 66.5% year-over-year, primarily due to decreased net revenue and transition-related expenses [21][22] - The company reported a net loss of $10.6 million or $5 per share, compared to a net income of $0.8 million or $0.13 per share in the prior year [23][24] Business Line Data and Key Metrics Changes - ADHD net revenue was $13.2 million, flat compared to Q1 2026, despite a slight decrease from the previous year, attributed to a shift in marketing focus towards EXXUA [16][19] - Pediatric portfolio revenue increased to $1.7 million from $715,000 in Q1 2026, but decreased from $2.7 million in the prior year [18][20] Market Data and Key Metrics Changes - The launch of EXXUA has seen prescriptions written from 27 states, with over 100 doctors prescribing it within the first month [13][14] - Most prescriptions are being filled through the RxConnect platform, with a significant portion also coming from retail pharmacies [46] Company Strategy and Development Direction - The company is focused on the commercial launch of EXXUA, the first FDA-approved 5-HT1A agonist for major depressive disorder, with a comprehensive strategy aimed at prescriber adoption and brand growth [4][31] - The marketing strategy includes a mix of personal and non-personal approaches, targeting high-volume antidepressant prescribers and leveraging the RxConnect platform for patient access [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early feedback from patients on EXXUA, noting good tolerability and satisfaction [15] - The company anticipates a gradual ramp-up in EXXUA net revenue as initial barriers to access are removed, with expectations for increased prescriptions ahead of revenue recognition [27][30] Other Important Information - The company incurred a one-time FDA PDUFA fee of $400,000 for Cotempla during the quarter [22] - Adjusted EBITDA was -$0.8 million for Q2 2026, down from $1.3 million in the prior year [25] Q&A Session Summary Question: Feedback from doctors prescribing EXXUA - Management noted mixed motivations for early prescriptions, including interest in the mechanism of action and ease of prescribing through RxConnect [33][34] Question: Expectations for sales force expansion - Management indicated that expansion would be unlikely in fiscal 2026, with triggers for expansion tied to achieving internal forecasts and cash flow [37][38] Question: Direct-to-consumer campaign details - The campaign will be web-based, focusing on search engine optimization and social media, while maintaining compliance with FDA regulations [39][40] Question: Impact of weather on prescription filling - Management confirmed significant weather impacts on script filling and shipments, but noted that supply issues have been corrected [44][51]

Aytu BioPharma Conference Summary Company Overview - **Company**: Aytu BioPharma (Ticker: AYTU) - **Industry**: Pharmaceuticals, specifically focusing on Central Nervous System (CNS) conditions, including ADHD and Major Depressive Disorder (MDD) [2][3] Key Points and Arguments Financial Performance - Aytu recently completed a successful fiscal year, reporting over **$66 million** in trailing 12-month net revenues [18][19] - The company has demonstrated consistent positive adjusted EBITDA in the **$9 to $10 million** range over the last three years [5][6] Strategic Realignment - Aytu has undergone a significant strategic realignment to focus on profitability by exiting unprofitable businesses and R&D programs [6][7] - The company divested its consumer health business and in-house manufacturing, which were costly and not aligned with its profitability goals [6][7] Product Portfolio - Aytu's primary focus is on its ADHD medications, including **Adzenys XR-ODT** and **Cotempla XR-ODT**, which are established brands in the market [9][10] - The company is preparing to launch a new antidepressant, **Exua**, targeting MDD, which is expected to be commercially available by the end of **2025** [11][12] Market Opportunity - The MDD market is substantial, with over **20 million** Americans affected and more than **340 million** prescriptions written annually [11][12] - Exua is positioned to address significant side effects associated with current antidepressants, such as sexual dysfunction and weight gain, making it a unique offering in the market [13][14][29] Unique Mechanism of Action - Exua targets the **5-HT1A receptor**, differentiating it from traditional SSRIs and SNRIs, which are known to cause side effects [14][29] - The product has been studied extensively, with over **5,000 patients** involved in clinical trials, demonstrating efficacy and safety [15][16] Commercial Strategy - Aytu has a dedicated **40-person sales force** focused on psychiatrists, which will facilitate the launch of Exua [27][28] - The company has established a patient access program, **Aytu ARCs Connect**, to ensure affordability and accessibility of its medications [20][21] Competitive Landscape - Exua is expected to be priced at a premium compared to other antidepressants, with a favorable reimbursement landscape, particularly for government programs like Medicaid and Medicare [32][33] - The product is patent protected through late **2030**, providing a significant competitive advantage [31] Future Outlook - Aytu is optimistic about the potential for Exua to capture market share, especially among patients dissatisfied with current treatment options due to side effects [41][42] - The company is well-funded with over **$30 million** in cash and a manageable debt load, positioning it for future growth [44] Additional Important Information - The company has made significant improvements in margins and cash flow due to its strategic changes [44] - Aytu's ADHD portfolio will continue to support the launch of Exua, leveraging existing relationships with prescribers [17][19] This summary encapsulates the key insights from Aytu BioPharma's conference, highlighting the company's strategic direction, product offerings, and market opportunities.